(EVGN) Evogene Ltd. VRIO Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(EVGN) Evogene Ltd. Complete Analysis Pack
Evogene VRIO: Competitive Edge, Durability, and Actionable Insights
Unlock Evogene Ltd.’s competitive DNA with the full VRIO Analysis—an actionable, company-specific review that shows which resources drive real advantage, how durable they are, and where management must act to sustain leadership; ideal for investors, analysts, consultants, and strategists seeking a ready-to-use Word and Excel toolkit.
Proprietary Computational Predictive Biology (CPB) platform
Value
Evogene Ltd.'s proprietary Computational Predictive Biology platform has clear value because it speeds discovery and raises hit quality across agriculture, human health, and industrial biology. That matters in a capital-heavy R&D model, where better early-stage filtering can cut wasted lab work and improve the odds of moving stronger candidates forward.
Rarity
Evogene Ltd.'s CPB platform is rare because curated, labeled life-science data tied to discovery assays is still hard to find and assemble; most biological data stays fragmented across studies, labs, and formats. That scarcity raises the barrier to entry, since building a usable dataset needs large, well-tagged assay outputs plus steady R&D spend, which smaller rivals usually lack.
Imitability
Evogene Ltd.’s proprietary Computational Predictive Biology (CPB) platform is hard to copy because patents can block direct replication of key methods, while trade secrets keep model logic and data workflows out of sight. That raises the imitability barrier and means rivals would need years of R&D to match the platform’s performance without a clear reverse-engineering path.
Organization
Evogene’s CPB platform is organized to source, manage, and renew alliance-based programs, which helps it turn model outputs into partnered R&D work instead of isolated code. That setup supports repeated deal flow, faster program handoffs, and lower execution risk, so the platform can stay useful across multiple partners and crop, health, and industrial programs.
Competitive Advantage
Evogene Ltd.'s proprietary Computational Predictive Biology (CPB) platform gives it a temporary competitive advantage by speeding target discovery and improving hit rates in product design. The edge is real but not permanent: as AI-driven biology tools spread and patents age, rivals can narrow the gap, so the moat depends on constant model upgrades and data accumulation.
Evogene’s CPB: A Data-Driven Moat in Faster Discovery
Evogene Ltd.'s CPB platform keeps value, rarity, and imitability advantages by turning proprietary biological data and model workflows into faster discovery across ag, health, and industrial programs. Its real edge comes from data depth and alliance execution, but the moat still depends on steady model refreshes and new assay data.
| VRIO factor | CPB platform |
|---|---|
| Value | Faster discovery |
| Rare | Hard-to-build data |
| Imitable | Patents plus trade secrets |
| Organized | Alliance-ready |
What is included in the product
Detailed Word Document
Assesses Evogene Ltd.’s strategic resources and capabilities to determine whether they are valuable, rare, hard to imitate, and well organized.
Customizable Excel Spreadsheet
Quickly identifies Evogene’s valuable, rare, and hard-to-copy resources to gauge competitive advantage and defensibility.
Reference Sources
Shows which Evogene resources are valuable, rare, hard to imitate, and organizationally supported to validate sustainable competitive advantages.
Curated proprietary biology and assay data assets
Value
Evogene Ltd.'s curated proprietary biology and assay data assets are valuable because they speed discovery and improve hit quality across agriculture, human health, and industrial biology. That data moat is hard to copy, and it supports faster target selection and screening decisions, which can cut wasted lab work and raise the odds of advancing better candidates.
Rarity
Curated, labeled life-science data tied to discovery assays is still scarce and fragmented, so Evogene Ltd. can treat this asset as rare in VRIO terms. The hard part is not volume alone, but linking clean labels to assay outcomes across many experiments.
That scarcity matters because most biotech data sit in separate lab systems, public databases, or vendor files, and that raises the cost and time needed to build comparable datasets. A proprietary, well-tagged dataset can therefore give Evogene Ltd. a defensible edge in target discovery and model training.
Imitability
Evogene Ltd.'s biology and assay data are hard to copy because patents can block direct replication, while its proprietary datasets and model logic are difficult to reverse engineer. That matters in a sector where building a validated discovery platform can take years and tens of millions of dollars, so the imitation barrier stays high.
Organization
Evogene is organized to source, manage, and renew alliance-based programs, which helps keep its curated biology and assay data assets active and reusable across partners. That structure supports faster program refresh and better capture of new data as alliances progress, so the asset base stays tied to live R&D output.
Competitive Advantage
Evogene Ltd.'s curated proprietary biology and assay data assets give it a temporary competitive advantage because they speed up target discovery and model training, but the edge is hard to keep if rivals build similar datasets. In 2025, the company still used these assets across its AI-driven programs, yet the value depends on continual data refresh, since data quality and scale can be copied over time.
Evogene’s Data Edge Is Valuable, Rare, and Hard to Copy
Evogene Ltd.'s curated biology and assay data stay valuable in FY2025 because they speed target discovery and improve hit quality, but the edge is only temporary if data refresh slows. The asset is rare and hard to copy, yet its real value comes from how well Evogene turns partner assays into reusable models.
| VRIO point | FY2025 read |
|---|---|
| Value | Faster discovery |
| Rarity | Scarce labeled assay data |
| Imitation | High cost to replicate |
Preview Before You Purchase
VRIO Analysis
The document you're previewing is the authentic Evogene Ltd. VRIO Analysis—not a mockup or sample—and it reflects the exact file you will receive after purchase; upon ordering, you'll instantly download this same professional, ready-to-edit document in Word and Excel formats with all content and pages included.
Patent portfolio and trade-secret know-how
Value
Evogene Ltd.’s patent portfolio and trade-secret know-how are valuable because they cut discovery time and lift hit quality across agriculture, human health, and industrial biology. Its 2025 platform work spans three core areas, so protected models and proprietary datasets help turn more inputs into better leads, faster.
Rarity
Curated, labeled life-science data tied to discovery assays is scarce and fragmented, so Evogene Ltd.'s patent portfolio and trade-secret know-how are rare assets. The real edge is not raw data, but assay-linked labels built over years, and that is hard for rivals to copy or buy quickly.
Imitability
Evogene Ltd.'s patent portfolio helps block direct copying, while its trade-secret know-how is hard to reverse engineer; U.S. utility patents last 20 years from filing, and trade secrets can protect value indefinitely if secrecy holds. That makes imitation costly and slow.
Organization
Evogene is organized to source, manage, and renew alliance-based programs through its business units and partner network, so its patent portfolio and trade-secret know-how are tied to repeatable external collaboration. In 2025, this setup helped support a model built around multiple active technology alliances rather than a single in-house product line.
Competitive Advantage
Evogene Ltd.'s patent portfolio and trade-secret know-how support a temporary competitive advantage because they slow imitation, but they do not create a permanent moat if rivals keep spending on AI-driven discovery and crop-input R&D. As a public agtech developer with ongoing losses in its latest filings, the value sits in speed to market and licensing leverage, not durable exclusivity.
Evogene’s IP Edge: Patents and Secrets Slow Copycats in 2025
Evogene Ltd.’s patent portfolio and trade-secret know-how support speed and selectivity in 2025 across ag-biotech, human health, and industrial biology. Utility patents can last 20 years from filing, while trade secrets can last indefinitely if kept confidential, so both raise the cost of imitation.
| Asset | Value |
|---|---|
| Patents | 20 years from filing |
| Trade secrets | Indefinite if secret |
| Strategic effect | Slower copying |
Strategic alliances with BASF, Corteva, Bayer, and Cannbit
Value
Evogene Ltd.'s alliances with BASF, Corteva, Bayer, and Cannbit add clear value by widening access to real partner data and speeding AI-led discovery across crop, human health, and industrial biology. In 2025, that matters because each better hit can cut screening time and raise success rates versus starting from scratch, which lifts the odds of faster pipeline wins.
Rarity
Evogene Ltd.’s alliances with four major partners, BASF, Corteva, Bayer, and Cannbit, make its curated, labeled discovery-assay data unusually rare. Most life-science data is still fragmented across silos, so building proprietary, assay-linked datasets like this takes years, high lab spend, and repeated validation.
Imitability
Evogene Ltd.’s alliances with BASF, Corteva, Bayer, and Cannbit are hard to copy because they sit on patented assets and know-how that trade secrets protect from easy reverse engineering. In practice, the barrier is not just the partnership list; it is the IP stack behind it, which makes direct imitation costly and slow.
Organization
Evogene is organized to source, manage, and renew alliance-based programs, with four named strategic partners here: BASF, Corteva, Bayer, and Cannbit. That partner set shows a repeatable model, not a one-off deal flow, which is a clear fit for the Organization test in VRIO.
Competitive Advantage
Evogene Ltd.’s alliances with BASF, Corteva, Bayer, and Cannbit create a temporary edge because they give access to large partner R&D budgets and field data, but the value is tied to contract renewals and project success. Corteva reported $16.9 billion in 2024 net sales, showing the scale Evogene can tap, yet that scale does not lock in a lasting moat.
Big-Pharma Alliances Give Evogene a Rare but Temporary Edge
Evogene Ltd.’s BASF, Corteva, Bayer, and Cannbit alliances are valuable because they plug Evogene into large R&D systems and real assay data. Corteva’s 2024 net sales were $16.9 billion, and BASF’s 2024 sales were €65.3 billion, so the partner base is big enough to keep feeding Evogene’s platform.
The edge is rare and hard to copy because these deals combine data, lab know-how, and IP. Still, the moat is only temporary because access depends on contract renewals and partner priorities.
| Partner | Latest scale | VRIO role |
|---|---|---|
| BASF | €65.3bn sales, 2024 | Data and validation access |
| Corteva | $16.9bn net sales, 2024 | Large R&D reach |
| Bayer | €46.6bn sales, 2024 | Discovery leverage |
| Cannbit | Partnered biology focus | Niche platform fit |
Cross-sector pipeline in agriculture, human health, industrial applications, and cannabis
Value
Value: Evogene Ltd.’s cross-sector pipeline links agriculture, human health, industrial biology, and cannabis, so the same AI and biological design engines can speed discovery and lift hit quality in multiple markets. That reuse helps cut screening waste and can widen the pool of usable candidates across four end markets at once.
Rarity
Curated, labeled life-science data tied to discovery assays is still scarce and fragmented, so Evogene Ltd.’s cross-sector pipeline in agriculture, human health, industrial applications, and cannabis draws on a hard-to-copy input. That makes the data layer rare, because most firms still rely on smaller, siloed, or weakly annotated datasets.
Imitability
Evogene Ltd.’s cross-sector pipeline is hard to copy because patents can block direct replication of platform outputs across agriculture, human health, industrial uses, and cannabis, while its trade secrets in gene discovery and predictive models are not easy to reverse engineer.
This keeps imitability low, since rivals would need both legal freedom and deep know-how to match the Company’s multi-vertical R&D engine.
Organization
Evogene is organized to source, manage, and renew alliance-based programs across agriculture, human health, industrial applications, and cannabis, which lets it keep multiple IP-led pipelines active at once. That structure supports repeat deal flow and lowers dependence on any single program, a fit for a company built around partnered R&D.
Competitive Advantage
Evogene Ltd.'s cross-sector pipeline spans 4 lanes: agriculture, human health, industrial uses, and cannabis, so it creates a temporary competitive advantage rather than a lasting one. The edge comes from shared computational biology and fast target discovery, but rivals can copy single programs; without broad, proven commercialization, the VRIO value is real, yet the rarity and durability are still limited.
Evogene’s AI Platform Spans 4 Markets, But Execution Is the Real Test
Evogene Ltd. uses one AI-led engine across 4 lanes: agriculture, human health, industrial applications, and cannabis. That breadth supports repeat use of the same data, models, and IP, so the pipeline can create value across multiple markets, but the edge is still easier to copy than a finished product.
| Metric | Data |
|---|---|
| Pipeline lanes | 4 |
| Main edge | Shared AI and biology stack |
| Copy risk | High at program level |
So the cross-sector setup is valuable and organized well, but its rarity and durability depend on turning more programs into real commercial wins.
Integrated AI, biology, and wet-lab scientific talent
Value
Evogene Ltd.'s integrated AI, biology, and wet-lab talent is valuable because it shortens discovery cycles and raises hit quality across agriculture, human health, and industrial biology. That mix lets the Company move from model design to lab validation faster, which is a real edge when R&D budgets are tight and each failed screen costs time and cash.
Rarity
Curated, labeled life-science data tied to discovery assays is still scarce and fragmented, even as AlphaFold DB now holds over 200 million predicted protein structures. That scarcity makes Evogene Ltd.’s AI, biology, and wet-lab talent harder to copy, because the value sits in the paired data, assay design, and biological know-how.
Imitability
Evogene Ltd.'s AI, biology, and wet-lab talent is hard to imitate because patents can block direct copying for 20 years from filing, while the firm’s proprietary know-how stays hidden as trade secrets. That mix matters in biotech, where a 2025 U.S. patent filing still takes years to fully publish and expose, but the wet-lab process details often never do.
Organization
Evogene is organized to source, manage, and renew alliance-based programs through its integrated AI, biology, and wet-lab teams, so partner deals can move from target selection to validation inside one system. That structure supports recurring collaboration revenue and faster program renewal, which is exactly what makes this capability valuable in a VRIO test.
Competitive Advantage
Evogene Ltd.’s edge comes from combining AI, biology, and wet-lab experts across 3 platform businesses, which speeds target discovery and validation. But this is a temporary competitive advantage: the know-how is valuable, yet it is easier to copy than hard IP, and the moat depends on keeping scarce talent and proprietary data ahead of rivals.
Evogene’s AI-Biology Edge Is Hard to Copy
Evogene Ltd.’s edge comes from one team linking AI, biology, and wet-lab work, which speeds model-to-test cycles and raises screen quality. That matters because AlphaFold DB now has over 200 million protein structures, but paired assay data and lab know-how are still scarce and hard to copy.
| Key VRIO data | Value |
|---|---|
| AlphaFold DB structures | 200M+ |
| Platform businesses | 3 |
Global operating footprint and trial access in the U.S., Israel, Brazil, and other markets
Value
Evogene Ltd.'s footprint in the U.S., Israel, Brazil, and other markets is valuable because it lets the company test genes and molecules in diverse field and lab conditions, which can speed discovery and improve hit quality across agriculture, human health, and industrial biology. That scale matters in a market where crop biotech trials often need multiple geographies to de-risk results before scale-up.
Rarity
Evogene Ltd.'s footprint across Israel, the U.S., Brazil, and other markets supports access to diverse trial sites, but the rare asset is the clean, labeled discovery data behind them. In life sciences, curated assay-linked datasets are still fragmented across many sources, so Evogene's ability to unify field and lab outputs is hard to copy.
Imitability
Evogene Ltd.’s U.S., Israel, Brazil, and other-market trial access is hard to copy because patent coverage can block direct imitation, while core know-how sits in trade secrets that rivals cannot easily reverse engineer. That matters in a market where Evogene listed 2024 revenue of $8.5 million, so protecting each field trial and platform detail helps defend scarce commercialization value.
Organization
Evogene is set up to source, run, and renew alliance-based programs across Israel, the U.S., Brazil, and other markets, so it can move trial access close to partners and local users. That networked model supports faster program resets and wider market reach, which is central to the Organization test in VRIO.
Competitive Advantage
Evogene’s footprint across the U.S., Israel, Brazil, and other markets gives it access to diverse trial sites and faster field validation, but the edge is temporary because local partners and peers can copy this reach. In 2025, this kind of multi-market access mainly helps speed product testing and de-risk development, not build a lasting moat.
Field Access Helps, but Data Network Is Evogene’s Real Edge
Evogene Ltd.’s U.S., Israel, Brazil, and other-market trial access supports faster validation across crops and biology settings, but it is not a strong moat by itself because rivals can also use local sites. The bigger edge is the linked field-and-lab data, which is harder to copy and more useful for repeat discovery.
| Metric | Data |
|---|---|
| 2024 revenue | $8.5 million |
| Core markets | U.S., Israel, Brazil |
| VRIO strength | Data network, not site access |
Licensing-led monetization and partner-development model
Value
Evogene Ltd.'s licensing-led model lets one discovery engine serve many partners, so it speeds screening and can lift hit quality across agriculture, human health, and industrial biology. That makes the asset hard to copy because the value sits in the software-plus-data platform, not just in one molecule or one deal.
By selling access and partner programs instead of only internal products, Evogene can reuse the same AI-led biology stack across multiple pipelines at once, which lowers marginal R&D cost and shortens time to a hit. The model is strongest when partner demand stays high, because each new license can scale the same core capability without rebuilding the platform.
Rarity
Evogene Ltd.'s data assets are rare because curated, labeled life-science datasets tied to discovery assays are hard to build and even harder to replicate. That scarcity supports licensing-led monetization: once a partner-developable dataset is trained and validated, it can be reused across multiple programs without rebuilding the underlying discovery stack.
Imitability
Evogene Ltd.'s licensing-led model is hard to copy because patents can block direct imitation for up to 20 years from filing, while trade secrets can stay protected indefinitely if kept confidential. That makes its partner-development know-how less exposed than a standard product business, so rivals face real legal and technical barriers.
Organization
Evogene is organized to source, manage, and renew alliance-based programs, so its licensing-led model is built into how the business runs. That setup helps turn proprietary tech into partner deals and keeps collaboration pipelines active across crop and health applications.
Competitive Advantage
Evogene Ltd.'s licensing-led model can create a temporary competitive advantage because it turns platform IP into partner-funded deals, limiting capital needs and speeding validation. The edge is real but not durable: once a target trait or digital-ag use case is proven, larger peers can copy, bid up royalties, or buy similar capabilities, so the moat stays narrow.
Evogene’s AI Platform Turns One Discovery Engine Into Repeat Deal Flow
Evogene Ltd.’s partner-led licensing model turns one AI discovery stack into repeatable deal flow, so the same core asset can support multiple crop, health, and industrial programs at once. The moat comes from curated datasets, validation know-how, and IP, where patents can protect inventions for up to 20 years from filing.
This can lift capital efficiency, but the edge stays narrow because proven traits or targets can draw larger rivals and press royalties.
| VRIO point | Key data |
|---|---|
| IP life | Up to 20 years |
| Model | One platform, many partners |
| Moat | Narrow, deal-driven |
Microbiome, seed-trait, and industrial-castor development expertise
Value
Evogene Ltd.’s microbiome, seed-trait, and industrial-castor expertise is valuable because it speeds target discovery and lifts hit quality across three end markets: agriculture, human health, and industrial biology. That breadth helps the company move faster from data to candidates, which can improve R&D productivity and reduce wasted screening cycles.
Rarity
Curated, labeled life-science data tied to discovery assays is rare because most data sits in separate silos, with no shared standards across microbiome, seed-trait, and industrial-castor work. That scarcity gives Evogene Ltd. a real rarity edge in VRIO: the value is not just the data, but the hard-to-replicate pairing of high-quality labels, assay history, and crop-specific biology.
Imitability
Evogene Ltd’s microbiome, seed-trait, and industrial-castor know-how is hard to copy because patents can block direct replication for up to 20 years from filing under standard patent law. That legal shield matters when gene-discovery and formulation data are tied to proprietary platforms.
Its trade secrets add another layer: the exact strain selection, trait models, and castor-development process are not easy to reverse engineer, so rivals face real delay and R&D cost.
Organization
Evogene is organized to source, manage, and renew alliance-based programs across 3 core areas: microbiome, seed-trait, and industrial-castor development. That structure fits its VRIO profile because it turns partner R&D into a repeatable operating model, which can keep programs moving even when internal cash spend stays tight.
Competitive Advantage
Evogene Ltd.’s microbiome, seed-trait, and industrial-castor know-how creates a temporary edge because it can speed target discovery and trait selection, but the IP and platform benefits are not hard to copy. In 2025, that edge still looks fragile: the value sits in fast R&D execution, not in a lasting moat that rivals cannot narrow with similar AI-led discovery tools.
Evogene’s rare biology edge speeds R&D, but the moat may not last
Evogene Ltd.’s microbiome, seed-trait, and industrial-castor expertise is valuable and rare because it links curated biology data to discovery assays across three markets, improving target selection and cuting screening waste. Its moat is only partly durable: patents can block copycats for up to 20 years, but AI-led discovery tools can still narrow the gap fast.
| VRIO point | Latest fact |
|---|---|
| IP term | Up to 20 years |
| Core domains | 3: microbiome, seed-trait, industrial-castor |
| Edge | Fast R&D, weak lasting moat |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.